Highlights GeNeuro SA

Equities

GNRO

CH0308403085

Real-time Euronext Paris Other stock markets 08:13:40 2024-05-21 am EDT			5-day change	1st Jan Change
1.8 ^EUR	-10.00%		+18.42%	+65.14%

May. 16	GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024	CI
Mar. 20	Geneuro SA Announces Appointments of Board of Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024	May. 16	CI
GeNeuro: share price falls after private placement	Feb. 02	CF
GeNeuro: Citigroup Global Markets Ltd crosses the 5% threshold	Jan. 05	CF
Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications	Dec. 11	CI
GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024	Nov. 28	CI
GeNeuro and Verily Collaborate to Advance Long-COVID Research	23-10-19	CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
GeNeuro in Collaboration with Heinrich-Heine University Announce Publication in PNAS of Results from their Joint Research on Role of HERV-W in MS	23-09-27	CI
GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients	23-09-11	CI
GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-05	CI
GeNeuro Lands EUR25 Million Loan to Advance Long COVID-19 Trial	23-03-07	MT
GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab	22-11-16	CI
Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms	22-10-28	CI
GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis	22-10-25	CI
GeNeuro SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-29	CI
GeNeuro SA Announces Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein and the Rationale for Targeted Therapy with Specific Antibody	22-08-30	CI
GeNeuro Wins Regulatory Nod To Launch Mid-stage Study Of Post-COVID-19 Drug In Switzerland	22-05-12	MT
Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes	22-05-11	CI
GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes	22-04-13	CI
GeNeuro SA Announces ProTEct-MS Phase 2 Trial Confirms Safety of Higher Doses of Temelimab and Synergistic Potential to Address Neurodegeneration on Top of Anti-inflammatory Treatment in Multiple Sclerosis	22-03-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GeNeuro SA

Equities

GNRO

CH0308403085

Highlights

Filters